Filing Flows › Kyntra Bio (KYNB) › Q4 2025 › vs Q3 2025
Kyntra Bio (KYNB) Q4 2025 vs Q3 2025 (quarter over quarter)
Kyntra Bio's revenue rose $201K (+19%) from $1.1M in Q3 2025 to $1.3M in Q4 2025.
Kyntra Bio, Q4 2025: revenue $1.3M (-59% year over year), net loss $14.2M, operating cash flow −$18.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3M | $1.1M | $201K | +19% |
| Net loss | $14.2M | −$201M | $215M | — |
| Costs & expenses | $15.5M | $207M | −$192M | -93% |
| Operating costs | $14.8M | $6.5M | $8.3M | +128% |
| Interest & other, net | $708K | −$206M | $207M | — |
| Research & development | $7.3M | $1.2M | $6.1M | +501% |
| SG&A | $7.2M | $5.3M | $2.0M | +37% |
| Operating cash sources | $19.5M | $2.5M | $17.0M | +678% |
| Share-based compensation | $1.2M | $662K | $527K | +80% |
| Cash used in operations | $18.3M | $1.8M | $16.5M | +892% |
| Net loss absorbed | $14.2M | −$201M | $215M | — |
| Working capital & other | $5.3M | $203M | −$198M | -97% |
Questions
How much did Kyntra Bio's revenue grow quarter over quarter in Q4 2025?
Kyntra Bio's revenue rose $201K (+19%) from $1.1M in Q3 2025 to $1.3M in Q4 2025.